This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignees: Amgen Fremont Inc., Dendreon Corporation. Active years: 2009.
Company Filing History:
1 out of 78 
1 out of 53 
Years Active: 2009
Title: Peter Koon Bong Ling: Innovator in Binding Proteins
Introduction
Peter Koon Bong Ling is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of binding proteins specific for human matriptase. His work has implications for the detection, prevention, and treatment of diseases, including cancer.
Latest Patents
Peter Koon Bong Ling holds a patent for binding proteins that are directed to the antigen matriptase. This patent includes fully human monoclonal antibodies and fragments thereof. The invention discloses nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to matriptase. Additionally, it reveals cell lines expressing such immunoglobulin molecules and monoclonal antibodies to matriptase. These antibodies can be utilized in various medical applications, particularly in oncology.
Career Highlights
Throughout his career, Peter has worked with prominent companies in the biotechnology sector. He has been associated with Dendreon Corporation and Amgen Fremont Inc., where he contributed to innovative research and development projects. His expertise in binding proteins has positioned him as a valuable asset in the field.
Collaborations
Peter has collaborated with several professionals in his field, including Caroline Darne Scatena and Ian Nevin Foltz. These collaborations have further enhanced his research and development efforts.
Conclusion
Peter Koon Bong Ling is a distinguished inventor whose work on binding proteins has the potential to impact cancer treatment significantly. His contributions to biotechnology continue to pave the way for advancements in medical science.